Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 16/20 | 0.71 |
| ▸ | WNT1 | P04628 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504369 | 0.85 | MAP3K8 (0.77) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6507621 | 0.83 | MAP3K8 (0.76) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6509322 | 0.83 | MAP3K8 (1.00) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL5508159 | 0.82 | MAP3K8 (0.63) | MAP3K8WNT1CLK2CLK3DYRK1A | |
| SCHEMBL6502024 | 0.78 | MAP3K8 (0.55) | MAP3K8WNT1CDK1CCNB1CCNA2 | |
| SCHEMBL6507308 | 0.77 | MAP3K8 (0.83) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6507878 | 0.74 | MAP3K8 (0.50) | MAP3K8WNT1CLK2CLK3DYRK1A | |
| SCHEMBL5517489 | 0.73 | MAP3K8 (0.51) | MAP3K8WNT1CLK2CLK3DYRK1A | |
| SCHEMBL6511342 | 0.73 | CDK1 (0.46) | MAP3K8WNT1CDK1CCNB1CCNA2 | |
| SCHEMBL6507542 | 0.72 | MAP3K8 (0.53) | MAP3K8WNT1CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | claimed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | MAP3K8 143/4885WNT1 640/4885CDK1 4/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAP3K8 8/4885WNT1 4322/4885CDK1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.